This pdf report contains information about TCR & CAR engineered T-cells and NK cells released during the month of September 2016. This issue forms part of the subscription service R&D and Business Tracker for TCR & CAR T-Cells and NK Cells which is listed in the "also available" below.
Featured presentations of September 2016 include the pipeline of CD33-targeted immunotherapeutics, the profile of US biotech Eureka Therapeutics and the profile of anti-glypican 3 CAR-T CSG-GPC3 from CARsGen Therapeutics.
The September 2016 issue of our R&D and Business Tracker service about TCR & CAR engineered T-cells and NK cells contains:
R&D and Technology Tracker
- Pipeline changes
- Regulatory news
- Technology validations
Business Tracker for:
- Company updates
- Merger & acquisitions
Clinical Trial Tracker:
- Scientific Publication Tracker
- Featured Cell Therapy Profile: CSG-GPC3
- Featured Company Profile: Eureka Therapuetics
- Featured Target or Technology Pipeline: CD33-Targeted Immunotherapeutics
- Antibody-Drug Conjugates
- Fc-Engineered Antibodies
- T-Cell and NK Cell Redirecting Bispecific Antibodies
- CAR T-Cells
Information about the CD33-Targeted Immunotherapeutics pipeline is provided in a tabular format and fully referenced.
Information released during the previous month is retrieved from a variety of sources including corporate press releases and statements, quarterly company business reports, SEC filings, company presentations, company websites, interviews, webcasts, journal articles, scientific abstracts and reviews, relevant scientific meetings, clinical trial databases, and proprietary database. Relevant information is presented in textual and tabular formats with disclosure of scientific references or by a hyperlink leading to the source of information.